Recurrent Squamous Cell Carcinoma of the Hypopharynx Completed Phase Trials for Gefitinib (DB00317)

IndicationStatusPhase
DBCOND0029504 (Recurrent Squamous Cell Carcinoma of the Hypopharynx)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00068497Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerTreatment